Interferon alpha (IFN alpha) ELISA Kit

CAT#: PBL41100-1

Specifications

Product Data

• Assay Length: 3.5 h
• Specificity:
  Performance Characteristics
  Inter-Assay CV: ≤ 8%
  Intra-Assay CV: ≤ 8%
  Spike Recovery: ≥ 90% in Serum

  Materials Provided:

  • Pre-coated microtiter plate(s)
  • Plate Sealers
  • Wash Solution Concentrate
  • Human Interferon Alpha Standard, 10,000 pg/ml
  • Dilution Buffer
  • Antibody Concentrate
  • HRP Conjugate Concentrate
  • Concentrate Diluent
  • TMB Substrate
  • Stop Solution
• Sensitivity: 10-500 pg/ml
• Reactivities: Human
• Components:

  Citations:
  1. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Golding et al., 2010, Immunology. 133(1):107-117. (link)
  2. Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Haseley et al., 2012, Cancer Research. 72(6):1353-1362. (link)

• Background:

  The VeriKine Human Interferon Alpha ELISA Kit has been developed to quantify levels of human IFN-alpha in cell or tissue culture media using a sandwich enzyme linked immunoassay (ELISA). The kit is based on an ELISA with anti-detection antibody conjugated to horseradish peroxidase (HRP). Tetramethyl-benzidine (TMB) is the substrate. The assay is based on the international reference standard for human interferon alpha (Hu-IFN-α) provided by the National Institutes of Health.

  Interferons (IFNs) are a family of mammalian cytokines produced by a variety of cells in response to viral infection, immunity stimulators and chemical inducers. They exhibit a wide range of biological activities that include antiviral, anti-proliferative and immunomodulatory functions. When IFN interacts with its cognate receptor, a signal is rapidly transmitted within the cell, often producing an antiviral state. The primary signal transduction cascade promoted by type I IFNs is the JAK1-STAT pathway. Activation of this signal transduction pathway leads to increased gene expression including (2’-5’) oligoadenylate synthetases, Mx proteins, and protein kinase R (PKR) that protect the cell from viral infection.

  Interferon Alpha (IFN-alpha), a type I interferon, was one of the first FDA approved biotherapeutic treatments. Accurate measurement of IFN-alpha in cell or tissue culture media allows evaluation of basic immune responses as well as assessing the potency of Toll-Like Receptor (TLR) agonist-based therapeutics in vitro.